BACKGROUND: Diabetes mellitus is associated with an increased incidence of colorectal cancer, but the impact of diabetes mellitus on colorectal cancer prognosis is not clear.
C olorectal cancer (CRC) is the third most common cancer worldwide after lung and breast cancer, with an estimated 1.24 million new cases diagnosed in 2008. 1 there is now ample evidence that diabetes mellitus is an independent risk factor for the development of CRC. [2] [3] [4] however, it is unclear if the presence of diabetes mellitus in patients with CRC is associated with prognosis after cancer diagnosis. improved understanding of these associations could have important public health implications given the increasing incidence of diabetes mellitus worldwide, 5 particularly among those 65 years and older who are at highest risk for CRC. 6 Conflicting results have been observed in previous studies of patients with colorectal cancer for both allcause 7-10 and cancer-specific mortality. [11] [12] [13] [14] a previous meta-analysis of 6 studies published before october 2008 revealed a 32% increase in all-cause mortality associated with diabetes mellitus, but reported no pooled estimate for cancer-specific mortality. 15 Because diabetes mellitus is the third highest noncancer cause of death among CRC patients and is strongly associated with cardiovascular disease, the leading cause of noncancer death in CRC patients, only limited conclusions about the effects of diabetes mellitus on cancer-related prognosis can be drawn from overall survival data. 9, [16] [17] [18] thus, cancer-specific mortality, disease-free survival, and recurrence should also be considered when determining the role of diabetes mellitus in CRC prognosis. since 2008, several large studies have reported estimates of the association between diabetes mellitus and both cancer-specific and all-cause mortality. 13, 16, 19, 20 these data provide an excellent opportunity to obtain more precise estimates of the association between diabetes mellitus and all-cause mortality and to conduct the first metaanalysis examining the relationship between diabetes mellitus and cancer-specific mortality. therefore, the goal of the current meta-analysis is to determine whether patients with CRC and diabetes mellitus have a higher risk for allcause and cancer-specific mortality relative to patients without diabetes mellitus. in addition, we examine the association between diabetes mellitus and both disease-free survival and cancer recurrence among those with CRC.
METHODS Eligibility Criteria
We included observational studies that identified patients with CRC and evaluated survival, cancer recurrence, and disease progression after CRC diagnosis according to diabetes status. studies reporting only postsurgical or in-hospital mortality were excluded. for inclusion, studies had to report hazard ratios or other relative risk estimates and variance (or data to calculate these) of all-cause or cancerspecific mortality, disease-free survival, or recurrence associated with diabetes mellitus. no language exclusions were made.
Search Strategy medline (through oViD) and embase were searched from inception to august 22, 2012 . the complete search strategy used for the oViD database is shown in appendix 1. titles and abstracts of all retrieved studies were then independently examined by 2 authors (G.G. and K.M.) to select potentially eligible studies for full-text review. full-text review was also conducted in duplicate. References of relevant studies and review articles were searched to identify any additional articles.
Data Extraction
Data extraction was conducted independently by 2 authors (G.G. and K.M.). Disagreements in data extraction were resolved by consensus. abstracted data included study population characteristics, CRC location, cancer stage, cancer treatment, duration of follow-up, adjustment variables, and relative risks and variance (or data to calculate these) of all-cause and cancer-specific mortality, diseasefree survival, and recurrence associated with diabetes mellitus. outcome effect estimates were abstracted overall and by type of cancer (colon or rectal). When multiple-effect estimates were reported, the most fully adjusted estimate was used. Corresponding authors were contacted for clarifications and for additional information when the data of interest were not initially reported.
to judge quality, information was abstracted by using elements of the strengthening the Reporting of observational Studies in Epidemiology (STROBE) checklist. 21 effect estimates, both within and among publications, were checked for overlapping patient populations. When 1 study had the same patients or was a subgroup of another study, the study with the most complete outcome information or the larger number of patients was included. When effect estimates had some overlapping and some nonoverlapping patients, owing to the use of the same cancer registry but with different inclusion criteria, for example, the largest study was included in the meta-analysis. a sensitivity analysis including all overlapping studies was done to assess the impact of excluding nonoverlapping individuals from overlapping studies in the pooled analyses.
Statistical Analysis
Relative risks (RRs) were used to examine the association between diabetes mellitus and both survival and recurrence in CRC patients. When estimates of the RR were not reported, the unadjusted RR and accompanying se were calculated from the 5-year survival rates reported by diabetes status. Relative risks and ses were logarithmically transformed to stabilize the variance and to normalize their distribution. We pooled RRs by using both fixed-effects and Dersimonian and laird random-effects models. 22 We used inverse variance weighting to calculate fixed-and random-effects summary estimates. formal statistical tests for heterogeneity were performed by using the Dersimonian and laird Q test and by examining the I 2 quantity. Because some evidence of heterogeneity was found, we present the more conservative results from the random-effects models. Results are presented both overall and by cancer-type subgroup. an influence analysis was conducted by excluding each study individually to test whether the removal of any study would influence the pooled summary estimates. additional sensitivity analyses were performed by restricting studies to those that included nonmetastatic patients only, to those with a minimum, mean, or median follow-up time of at least 3 years, to those that presented appropriately adjusted effect estimates (at least age and cancer stage adjustment), and by including all studies with overlapping participants. Publication bias was assessed by using the Begg and Egger tests. We conducted all analyses using stata software, version 10.1 (stata Corp, College station, tX).
RESULTS
the study selection process for inclusion in the metaanalysis is illustrated in figure 1 . of the 1238 nonduplicate abstracts reviewed, 91 were included in the full-text review, and 26 of those met our inclusion criteria. two articles were excluded because the patient population was a subgroup of a larger study. 23, 24 three studies were excluded because they had partially overlapping patient populations with larger studies because of the use of the same tumor registry or hospital population. [25] [26] [27] to avoid including participants in the analyses more than once, the smaller studies were excluded from the primary analyses, but were included in a sensitivity analysis. an additional overlapping study was not included in the main analyses, but was included in an a priori sensitivity analysis that did not include the larger overlapping study. 28 one study reported estimates for diabetes mellitus with complications and diabetes mellitus without complications both compared with the same nondiabetic group. 29 in this case, the estimate with the largest sample size (diabetes mellitus without complications) was used in the main analysis and both estimates were included in the sensitivity analysis. overall, 26 articles met the inclusion criteria and were included in the meta-analysis.
Description and Quality of Studies
Characteristics of the 26 included studies are summarized in table 1. all studies, with the exception of one, were published in the past 10 years. 11 there were 7 prospective cohort studies, including 3 nationwide prospective mortality studies 10, 11, 16 and 1 follow-up of a chemotherapy trial. 8 all the other studies were retrospective cohort studies, including an age-and sex-matched cohort study. 39 all studies were limited to patients with invasive colorectal adenocarcinoma, with the exception of one study that included 124 of 1853 patients with noninvasive colon cancer. 38 ten of the 26 studies reported results restricted to those without metastatic disease. 8, 9, 16, 19, 20, 28, 35, 40, 41 eleven studies included only patients undergoing surgery, 7, 8, 16, 19, 28, [32] [33] [34] 36, 41 and, in 10 studies, treatment was not reported. [9] [10] [11] [12] [13] [14] 37, 38, 40, 42 the quality analysis of the studies is presented in table 2. ten of the studies were population based, [9] [10] [11] [12] 14, 16, 20, 37, 40, 42 one was a cohort based on a multicenter trial, 8 and all others were from single institutions. there were 12 studies in which the outcomes were not adjusted for the age of the patient or for tumor stage. 7 figure 2 shows the RR of all-cause mortality ( fig. 2a ), cancer-specific mortality ( Fig. 2B the results from the subgroup analysis by cancer type are presented in figure 3 . Diabetes mellitus was associated with all-cause mortality in both colon (RR, 1.17; 95% Ci, 1.07-1.29) and rectal (RR, 1.18; 95% Ci, 1.08-1.29) cancer patients with similar results obtained for the 2 cancer types ( fig. 3a ). Diabetes mellitus was also associated with cancer-specific mortality in both colon (RR. 1.22; 95% Ci, 1.08-1.39) and rectal (RR, 1.23; 95% Ci, 1.13-1.33) cancer patients ( Fig. 3B ).
All-Cause and Cancer-Specific Mortality
there was some evidence of publication bias for the all-cause mortality analysis (egger p-value = 0.05; Begg p-value = 0.3). use of the trim-and-fill method to obtain an adjusted estimate in the presence of publication bias attenuated the association (RR, 1.03; 95% Ci, 0.96-1.11) suggesting that the observed diabetes mellitus and allcause mortality association could be due to publication bias. there was no evidence of publication bias for cancerspecific mortality (egger p-value = 0.1; Begg p-value = 0.7), with no difference in the adjusted RR estimated by using the trim-and-fill method (RR, 1.12; 95% Ci, 1.02-1.24). Because the meta-analyses of disease-free survival and recurrence included only 3 studies each, analyses of publication bias would be severely underpowered and were not conducted. Table 3 shows results of the 3 sensitivity analyses. Because prognosis after CRC diagnosis is very different for those with metastatic and nonmetastatic cancer, we conducted a sensitivity analysis restricted to nonmetastatic cancers and observed stronger associations between diabetes mellitus and both all-cause (RR, 1.32; 95% Ci, 1.21, 1.44) and cancer-specific (RR, 1.27; 95% Ci, 1.06-1.52) mortality.
Sensitivity Analysis
Restricting the analyses to studies that had at least 3 years of follow-up also resulted in a stronger association with all-cause (RR, 1.25; 95% Ci, 1.15-1.36) and cancer-specific mortality (RR, 1.27; 95%Ci, 1.14-1. 40 ). in addition, restricting the analyses to estimates that were appropriately adjusted for age and stage at diagnosis did not sub-stantially change the magnitude of the effect estimates. in addition, including all overlapping studies did not meaningfully change the all-cause mortality pooled estimate. the cause-specific mortality, disease-free survival, and recurrence end points did not have any overlapping studies. furthermore, the removal of any individual study from each of the 4 meta-analyses did not have a substantial impact on the pooled-effect estimates (data not shown).
DISCUSSION
our meta-analysis of 21 studies reporting overall mortality, including 216,981 participants, showed that diabetes mellitus is associated with a 17% increased risk of all-cause mortality in patients with CRC. the reason for this association has previously been attributed to the general effects of diabetes mellitus on mortality including increased death from cardiovascular disease 9,16-18 and increased perioperative mortality. 15 however, our meta-analysis of cancer-specific outcomes suggests that the increased risk of all-cause mortality is at least in part due to an increase in deaths from CRC and to an increased recurrence rate in diabetic patients. a higher risk of cancer-specific mortality for those with diabetes mellitus could be attributed to several factors. first, diabetic patients may present with more advanced CRC because of the underuse of screening. 43 however, of the studies included in this meta-analysis, only one reported advanced tumor stage in diabetic patients compared with nondiabetic patients. 32 in addition, 3 studies found a lower incidence of malignant bowel obstruction in patients with diabetes mellitus than in those without diabetes mellitus. 8, 13, 30 therefore, the difference in prognosis cannot be readily explained by a more advanced stage at diagnosis in those with diabetes mellitus. a second possible explanation is that the difference in cancer-related mortality in diabetic patients may be due to less aggressive cancer treatment, a finding reported by 3 of the studies included in the current meta-analysis. 9,20,31 treatment differences could be related to underlying diabetes mellitus-related comorbidities that influence clinical decision making or to higher treatment-related toxicities in diabetic patients. 44, 45 moreover, a recent study reported a lower response rate to chemoradiotherapy in patients with rectal cancer who have diabetes mellitus in comparison with those who do not have diabetes mellitus. 46 these data suggest not only that diabetic patients are receiving less aggressive treatment, but also that they are not responding as well to the treatment as those who do not have diabetes mellitus.
a third possibility is that hyperinsulinemia or increased levels of insulin-like growth factors (IGFs) may influence tumor aggressiveness. 2 in hyperinsulinemia, insulin binds to the IGF-1 receptor and works in competition with IGF binding proteins to increase free IGF-1 levels in the blood. 47 insulin-like growth factors have been shown to promote tumor cell proliferation and angiogenesis. 48 Moreover, IGF binding proteins levels have been inversely correlated with CRC mortality. 49, 50 insulin resistance is also considered to be an underlying cause for the correlation between obesity and CRC incidence. 2, 51 however, the association between hyperinsulinemia and CRC mortality is unclear. although 1 study showed an increase in overall and CRC-specific mortality in diabetic patients with high hemoglobin a1c, 39 a recent large study found no influence of insulin use on CRC-specific mortality in type 2 diabetic patients. 18 Recent observational studies showed that the use of the antihyperglycemic agent metformin is associated with a decreased incidence of CRC 52, 53 and reduction in CRCrelated deaths, 54, 55 suggesting that metformin may have a potential use in CRC prevention and treatment. interestingly, metformin not only decreases insulin resistance and lowers IGF-1 levels, but also inhibits the mammalian target of rapamycin-controlled synthesis of key proteins responsible for the malignant phenotypes of cancer cells, as well as angiogenesis. 56 a recent trial of metformin given to patients with breast cancer 4 weeks before surgery failed to show a significant decrease of the Ki-67 levels in the tumor specimen in comparison with placebo. 57 however, there was a significant decrease of Ki-67 levels in pa-tients with high homeostasis model assessment (homa) index (the ratio of fasting blood glucose to insulin) compared with patients with low homa index, and similar Ki-67 trends in patients with higher BMI, waist-hip ratio, and C-reactive protein levels. these results suggest that the antitumoral effect of metformin may be limited to patients with insulin resistance and metabolic syndrome. at this time, several phase ii and iii trials are testing the effects of metformin, alone or in combination with other drugs, on decreasing the risk of recurrence in both diabetic and nondiabetic breast, pancreatic, and prostate cancer patients. 58 the results of our meta-analysis suggest the need for adjuvant trials of metformin in CRC as well as the need to assess different therapeutic and lifestyle interventions, because low dietary glycemic load and physical exercise have been shown to be associated with improved survival after CRC diagnosis. 59, 60 in addition, screening guidelines for diabetes mellitus in CRC patients should be implemented to diagnose insulin resistance early with the use of reliable indicators such as the homa index, and metformin should be regarded as the antidiabetic drug of choice in CRC patients who have diabetes mellitus or glucose intolerance, as has been advocated for patients who have breast cancer. 61 28 x x Zhou et al (2011) 41 x x x = present in study. our sensitivity analyses show that if patients who have metastatic disease at presentation are eliminated from the analysis, the associations between diabetes mellitus and both all-cause and cancer-specific mortality become stronger. Given the unanimous fatal outcome of patients with metastatic CRC, limiting the analysis to patients with a chance for long-term survival gives us an opportunity to better estimate the association between diabetes mellitus and CRC outcomes. this is also reflected in the stronger association found between diabetes mellitus and both all-cause and cancer-specific mortality after eliminating studies with insufficient follow-up. it is possible that the risk of recurrence increases with a longer exposure to diabetes mellitus, as has been shown for the risk of developing new cancer. 62 the main strength of this meta-analysis is our comprehensive search strategy and the number of recent relevant publications identified. this allowed us to pool results for not only all-cause mortality, but also for cancer-specific mortality, disease-free survival, and recurrence. in addition, the number of included studies allowed us to conduct some sensitivity analyses to assess the quality of the included studies and to explore additional a priori hypotheses.
our study also has several limitations. first, our meta-analysis included some studies that did not adjust for age and cancer stage, which are important confounding variables that should be considered in these analyses. however, after restricting our analyses to only those studies with age and stage adjustment, the magnitude of the associations for all-cause and cancer-specific mortality were similar to those when all studies are included, suggesting that lack of adjustment for age and stage did not substantially impact our results. moreover, several studies included in this meta-analysis fail to adjust for one or more confounding variables frequent in diabetic patients, such as the presence of cardiovascular disease, neurovascular disease, and inadequacy of adjuvant therapy. second, some studies have short follow-up or do not report mean or median follow-up. however, after eliminating studies with insufficient follow-up, the association between diabetes mellitus and poor prognosis persisted and became stronger. third, many studies did not limit their patient population to those with nonmetastatic disease. our sensitivity analysis showed that, if studies had been restricted to nonmetastatic patients, stronger associations would likely be observed. fourth, the included studies were somewhat heterogeneous in study popula- 7 Meyerhardt et al 8 Gross et al 9 Park et al 10,* Shonka et al 38 Siddiqui et al 39 Jullumstro et al 35 Chen et al 30 Chiao et al 31 Gao et al 33 Noh et al 36 Feng et al 32 Huang et al 13 Lai et al 19 Lieffers et al 29 Sarfati et al 37 Tiwana et al 40 for potential publication bias (data not shown), strongly support an association between diabetes mellitus and allcause mortality in CRC patients.
CONCLUSION
our meta-analysis found that CRC patients who have diabetes mellitus have a significantly increased risk of allcause mortality and cancer-specific mortality and a sig-nificantly reduced disease-free survival. further research is needed to assess the effect of different treatments on this adverse prognosis.
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